Intra-arterial chemotherapy for retinoblastoma: Our first three-and-a-half years' experience in Malaysia

Autor: Chee Chung Liu, Norhafizah Hamzah, Nurliza Khaliddin, Jia Him Lau, Jamalia Rahmat, Adzleen Mohmood
Rok vydání: 2019
Předmět:
Melphalan
Male
Eye Diseases
medicine.medical_treatment
Ophthalmologic Tumors
Intra arterial chemotherapy
Cancer Treatment
Salvage therapy
0302 clinical medicine
Medicine and Health Sciences
Blastomas
Multidisciplinary
Retinoblastoma
Pharmaceutics
Arteries
Treatment Outcome
Oncology
Optical Equipment
030220 oncology & carcinogenesis
Child
Preschool
Medicine
Engineering and Technology
Female
Anatomy
medicine.drug
Research Article
Clinical Oncology
medicine.medical_specialty
Science
Retinal Neoplasms
Enucleation
Equipment
03 medical and health sciences
Cancer Chemotherapy
Drug Therapy
Ocular System
medicine
Humans
Infusions
Intra-Arterial
Chemotherapy
Adverse effect
Antineoplastic Agents
Alkylating
Retrospective Studies
Salvage Therapy
business.industry
Lasers
Malaysia
Infant
Biology and Life Sciences
Cancers and Neoplasms
Retrospective cohort study
medicine.disease
eye diseases
Surgery
Ophthalmology
030221 ophthalmology & optometry
Cardiovascular Anatomy
Eyes
Blood Vessels
Clinical Medicine
business
Head
Zdroj: PLoS ONE
PLoS ONE, Vol 15, Iss 5, p e0232249 (2020)
ISSN: 1932-6203
Popis: Aim To report our first three-and-a-half years' experience with intra-arterial chemotherapy (IAC) in managing retinoblastoma (RB). Methods Single institution, retrospective, interventional case series of 14 retinoblastoma patients managed with IAC from December 2014 to June 2018. Demographics were described. Outcomes measures were tumor response, treatment complications and globe salvage. Results Subjects' mean age at the first administration of IAC was 31.4 months. 57.1% of the eyes were Group D and E retinoblastoma, while 79% were bilateral disease. 93% of the eyes were as secondary treatment. Of 32 IAC cannulations performed, 23 (71.8%) were successful and received chemotherapy drug melphalan. Each eye received a mean of 1.8 (range 1-4) IAC injections. 53% of the eyes showed regression post treatment. After a mean follow up period of 19 months, globe salvage rate was 38%. Most of the adverse effects experienced were localized and transient. Conclusion IAC has provided an added recourse in the armamentarium of retinoblastoma treatment in our center. IAC treatment is a viable alternative in the treatment of retinoblastoma to salvage globe, for eyes that would conventionally require enucleation especially in bilateral disease.
Databáze: OpenAIRE
Externí odkaz: